Back to Search
Start Over
Immune killer cells treatment for previously treated stage IV NSCLC patients.
- Source :
-
Scientific reports [Sci Rep] 2024 Aug 21; Vol. 14 (1), pp. 19374. Date of Electronic Publication: 2024 Aug 21. - Publication Year :
- 2024
-
Abstract
- The 5-year survival is poor for stage IV non-small cell lung cancer (NSCLC). Recently, cell immunotherapy has emerged as a new treatment strategy. This study aimed to evaluate the efficacy and safety of Immune killer cells (IKC) in patients with stage IV NSCLC after the failure of prior chemotherapy. This study enrolled 26 patients with stage IV NSCLC who failed at least two lines of chemotherapy with or without targeted therapy. The IKC was given alone weekly for 24 weeks. The primary endpoint was progression-free survival (PFS). Secondary outcomes included overall survival (OS), pain intensity, quality of life (QOL), and safety. The median PFS for the intent-to-treat (ITT) population (i.e., all enrolled patients) was 3.8 month. In the per-protocol (PP) population (i.e., patients receiving > 12 IKC infusions), the median PFS was 5.6 months. Moreover, the ITT population showed a 1-year survival rate of 60.0%, while that for the PP population was 85.7%. Only 7 out of 200 AEs (3.5%) were related to the IKC infusion, and they were all rated as grade 1 in severity. The IKC infusion was well tolerated. This novel immunotherapy prolonged the PFS and improved the survival compared with historical data. It might be a potential treatment strategy for stage IV NSCLC patient who failed prior chemotherapy.ClinicalTrials.gov identifier: NCT03499834.<br /> (© 2024. The Author(s).)
- Subjects :
- Humans
Male
Female
Middle Aged
Aged
Quality of Life
Progression-Free Survival
Adult
Treatment Outcome
Immunotherapy, Adoptive methods
Immunotherapy, Adoptive adverse effects
Carcinoma, Non-Small-Cell Lung therapy
Carcinoma, Non-Small-Cell Lung immunology
Carcinoma, Non-Small-Cell Lung pathology
Carcinoma, Non-Small-Cell Lung mortality
Lung Neoplasms therapy
Lung Neoplasms immunology
Lung Neoplasms pathology
Lung Neoplasms mortality
Neoplasm Staging
Subjects
Details
- Language :
- English
- ISSN :
- 2045-2322
- Volume :
- 14
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Scientific reports
- Publication Type :
- Academic Journal
- Accession number :
- 39169058
- Full Text :
- https://doi.org/10.1038/s41598-024-69587-x